Kawasaki disease

Comprehensive Therapy

Volumn 23, Issue 1, 1997, Pages 13-18

  Shulman, Stanford T ^a,b   Bendet, Moshe ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b CHILDREN'S MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACUTE PHASE PROTEIN; ANTIPYRETIC AGENT; C REACTIVE PROTEIN; CORTICOSTEROID; DIPYRIDAMOLE; IMMUNOGLOBULIN; NONSTEROID ANTIINFLAMMATORY AGENT;

CHILD; CLINICAL FEATURE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE COURSE; ECHOCARDIOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; FEVER; HEALTH SURVEY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ISCHEMIC HEART DISEASE; MUCOCUTANEOUS LYMPH NODE SYNDROME; REVIEW; SIDE EFFECT; TREATMENT OUTCOME;

ASPIRIN; CHILD; CHILD, PRESCHOOL; CORONARY DISEASE; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT; JAPAN; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; RISK FACTORS;

EID: 0031018061     PISSN: 00988243     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children (Japanese). Jpn J Allerg. 1967;16:178222.
2. Melish ME, Hicks RM, Larson EJ. Mucocutaneous lymph node syndrome in the United States. Am JDis Child. 1976;130:599-607.
3. Centers for Disease Control. Kawasaki Disease: New York. MMWR. 1980;29:61-63.
4. Kawasaki T, Kosaki F, Okawa S, et al. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics. 1974;54:271-276.
5. Shulman ST, McAuley JB, Pachman LM, et al. Epidemiology of Kawasaki syndrome in an urban U.S. area with a small Asian population. Am J Dis Child. 1987;141:420-425.
6. Yanagawa H, Yashiro M, Nakamura Y, et al. Epidemiologie picture of Kawasaki Disease in Japan. Pediatrics. 1995;95:475-479.
7. Taubert K, Rowley AH, Shulman ST. A 10 year (1984-1993) U.S. hospital survey of Kawasaki Disease. In: Kato H, ed. Kawasaki Disease. Amsterdam: Elsevier; 1995:34-38.
8. Shulman ST, Delnocencio J, Hirsch R. Kawasaki Disease. Pédiatrie Clinics of North America. 1995;42:1205-1222.
9. Leung DYM, Meissner HC, Fulton DR, et al. Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome. Lancet. 1993;342:1385-1387.
10. Deresiewicz RL, Flaxenburg J, Leng K, et al. Sequence of the toxic shock syndrome toxin gene (tstH) borne by strains of Staphylococcus aureus isolated from patients with Kawasaki syndrome. Inf'&Imm. 1996;64:3374-3396.
11. Terai M, Miwa K, Williams T, et al. The absence of evidence of staphylococcal toxin involvement in the pathogenesis of Kawasaki Disease. J Infect Dis. 1995;172:558-561.
12. Nash MC, Shah V, Dillon MJ. Soluble cell adhesion molecules and vonWillebrand factor in children with Kawasaki Disease. Clin Exp Immun. 1995;101:13-17.
13. Pietra BA, Delnocencio J, Giannini EH, et al. TCR V family repertoire and T cell activation markers in Kawasaki Disease. / Immunol. 1994; 153:1881-1888.
14. Rowley AH, Gonzalez-Crussi F, Gidding SS, Shulman ST. Incomplete KD with coronary artery involvement. / Pediatr. 1987;110:409-413.
15. Kim-Stamos J, Corydon K, Donaldson J, Shulman ST. Lymphadenitis as the dominant presentation of Kawasaki disease. Pediatrics. 1994; 93:525-528.
16. Kimura A, Inoue O, Kato H. Serum concentrations of total bile acids in patients with acute Kawasaki syndrome. Arch Pediatr Adol Med. 1996:150:289-292.
17. Rosenfeld EA, Corydon KE, Shulman ST. Kawasaki Disease in infants less than one year of age. /Pediatr. 1995;126:524-529.
18. Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gammaglobulin. N Engl J Med. 1986;315:341-347.
19. Newburger JW, Takahashi M, Beiser AS, et al. A single infusion of intravenous gamma globulin compared to four daily doses in the treatment of acute Kawasaki syndrome. N Engl J Med. 1991;324:1633-1639.
20. Terai M, Shulman ST. The prevalence of coronary artery abnormalities in Kawasaki Disease is highly dependent on gamma globulin dose but independent of salicylate dose. In press.
21. Kato H, Koike S, Yokoyama T. Kawasaki Disease: effect of treatment on coronary artery involvement. Pediatrics. 1979;63:175-179.
22. Kitamura S, Kamedo Y, Sekit S, et al. Longterm outcome of myocardial revascularization in patients with Kawasaki coronary artery disease. J Thorac Cardiovasc Surg. 1994;107:663674.
23. Checchia P, Pahl E, Shulman ST. The worldwide experience with cardiac transplantation for Kawasaki Disease. Pediatrics. In press.